Prevalence of antimicrobial-resistant Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis

Introduction. Violation of sputum evacuation in patients with cystic fibrosis leads to the persistence of microorganisms. Most often, the microorganisms are isolated from sputum in patients with cystic fibrosis: Staphylococcus aureus, Pseudomonas aeruginosa, Burkholderia cepacia complex, etc. For the treatment of infections caused by P. aeruginosa, the following groups of antibiotics are used: aminoglycosides, carbapenems, polymyxins, cephalosporins, fluoroquinolones, inhibitor-protected penicillins and fosfomycin.

Aim. To the study is to determine antimicrobial resistance in P. aeruginosa isolated from patients with cystic fibrosis.

Materials and methods. An analysis of 87 results of sputum, biomaterial from the posterior wall of the pharynx and nose was made.

Results and discussion. Biomaterial was taken from the nasal in 4.6% cases, from the posterior pharyngeal wall in 35.6% and sputum in 59.8%. The lowest level of resistance was registered in strains isolated from the nasal cavity. Microorganisms isolated from the posterior pharyngeal wall showed a higher level of antibiotic resistance. The sensitivity data of sputum isolates were similar to the results from the posterior pharyngeal wall. The highest level of resistance was obtained to aminoglycosides (19.3%) and carbapenems (14.8%). In addition, 12.5% of P. aeruginosa isolates were resistant to sodium colistimethate, 10.2% to fluoroquinolones. The lowest level of insensitivity was found to cephalosporins (5.7%) and protected beta-lactams (4.5%). The revealed trend of decreasing sensitivity, in our opinion, is associated with a greater frequency of antibiotic use.

Conclusion. Chronic P. aeruginosa infection in patients with CF contributes to a more severe course of the disease and increases the risk of complications.

1. Баранов АА, Намазова-Баранова ЛС, Куцев СИ, Авдеев СН, Полевиченко ЕВ, Белевский АС и др. Кистозный фиброз (муковисцидоз): клинические рекомендации. М.; 2021. 225 с. Режим доступа: https://cr.minzdrav.gov.ru/recomend/372_2.

2. Evstratov AA, Cheremisin AE, Abbazov RR, Sabirova DR. Cystic fibrosis as a multisided problem. Literature review and clinical examples. Practical Medicine. 2019;17(6-1):11–14. (In Russ.) https://doi.org/10.32000/2072-1757-2019-6-11-14.

3. Dickinson KM, Collaco JM. Cystic Fibrosis. Pediatr Rev. 2021;42(2):55–67. https://doi.org/10.1542/pir.2019-0212.

4. Kondratyeva EI, Amelina EL, Chernukha MYu, Sherman VD, Krasovskiy SA, Kashirskaya NYu et al. Review of clinical guidelines “Cystic fibrosis”, 2020. Pulmonologiya. 2021;31(2):135–146. (In Russ.) https://doi.org/10.18093/0869-0189-2021-31-2-135-146.

5. Baranov AA, Namazova-Baranova LS, Kutsev SI, Avdeev SN, Polevichenko EV, Belevskiy AS et al. Modern approaches in management of children with cystic fibrosis. Pediatric Pharmacology. 2022;19(2):153–195. (In Russ.) https://doi.org/10.15690/pf.v19i2.2417.

6. Kondratyeva EI, Voronkova AYu, Kashirskaya NYu, Krasovsky SA, Starinova MA, Amelina EL et al. Russian registry of patients with cystic fibrosis: lessons and perspectives. Pulmonologiya. 2023;33(2):171–181. (In Russ.) https://doi.org/10.18093/0869-0189-2023-33-2-171-181.

7. Yashin SS, Yunusova YuR, Isakova NV, Serdobolskaya YuV. Cystic fibrosis. Modern Problems of Science and Education. 2022;(5). (In Russ.) https://doi.org/10.17513/spno.32008.

8. Shaginyan IA, Avetisyan LR, Chernukha MYu, Siyanova EA, Burmistrov EM, Voronkova AYu et al. Epidemiological significance of genome variations in Pseudomonas aeruginosa causing chronic lung infection in patients with cystic fibrosis. Clinical Microbiology and Antimicrobial Chemotherapy. 2019; 21(4):340–351. (In Russ.) https://doi.org/10.36488/cmac.2019.4.340-351.

9. Kharchenko LA. Pseudomonas aeruginosa: modern realities of antibacterial therapy. Emergency Medicine. 2015;(1):164–168. (In Russ.) Available at: http://www.mif-ua.com/archive/article/40240.

10. Li W, Yan F, Zhou H, Lin X, Wu Y, Chen C et al. P. aeruginosa lipopolysaccharide-induced MUC5AC and CLCA3 expression is partly through Duox1 in vitro and in vivo. PLoS ONE. 2013;8(5):e63945. https://doi.org/10.1371/journal.pone.0063945.

11. Yan S, Wu G. Can Biofilm Be Reversed Through Quorum Sensing in Pseudomonas aeruginosa? Front Microbiol. 2019;10:1582. https://doi.org/10.3389/fmicb.2019.01582.

12. Jurado-Martín I, Sainz-Mejías M, McClean S. Pseudomonas aeruginosa: An Audacious Pathogen with an Adaptable Arsenal of Virulence Factors. Int J Mol Sci. 2021;22(6):3128. https://doi.org/10.3390/ijms22063128.

13. Anantharajah A, Mingeot-Leclercq MP, Van Bambeke F. Targeting the Type Three Secretion System in Pseudomonas aeruginosa. Trends Pharmacol Sci. 2016;37(9):734–749. https://doi.org/10.1016/j.tips.2016.05.011.

14. Kozlov AV, Lyamin AV, Zhestkov AV, Gusyakova OA, Khaliulin AV. Iron metabolism in bacterial cells: from physiological significance to a new class of antimicrobial agents. Clinical Microbiology and Antimicrobial Chemotherapy. 2022;24(2):165–170. (In Russ.) https://doi.org/10.36488/cmac.2022.2.165-170.

15. Lee J, Zhang L. The hierarchy quorum sensing network in Pseudomonas aeruginosa. Protein Cell. 2015;6(1):26–41. https://doi.org/10.1007/s13238-014-0100-x.

16. Riquelme SA, Liimatta K, Wong Fok Lung T, Fields B, Ahn D, Chen D et al. Pseudomonas aeruginosa Utilizes Host-Derived Itaconate to Redirect Its Metabolism to Promote Biofilm Formation. Cell Metab. 2020;31(6):1091–1106. e6. https://doi.org/10.1016/j.cmet.2020.04.017.

17. Malone JG. Role of small colony variants in persistence of Pseudomonas aeruginosa infections in cystic fibrosis lungs. Infect Drug Resist. 2015;8:237–247. https://doi.org/10.2147/IDR.S68214.

18. Maldonado RF, Sá-Correia I, Valvano MA. Lipopolysaccharide modification in Gram-negative bacteria during chronic infection. FEMS Microbiol Rev. 2016;40(4):480–493. https://doi.org/10.1093/femsre/fuw007.

19. Skleenova EYu, Azizov IS, Shek EA, Eidelstein MV, Kozlov RS, Dekhnich AV. Pseudomonas aeruginosa in the Russian Federation: the history of one of the most successful nosocomial pathogens. Clinical Microbiology and Antimicrobial Chemotherapy. 2018;20(3):164–171. (In Russ.) https://doi.org/10.36488/cmac.2018.3.164-171.

20. Eidelshtein MV, Shek EA, Sukhorukova MV, Skleenova EYu, Ivanchik NV, Shaydullina ER et al. Antibiotic resistance, carbapenemase production and genotypes nosocomial strains of Pseudomonas aeruginosa in hospitals Russia: results of a multicenter epidemiological research MARATHON 2015–2016. Clinical Microbiology and Antimicrobial Chemotherapy. 2019;21(2):160–170. (In Russ.) https://doi.org/10.36488/cmac.2019.2.160-170.

21. Polikarpova SV, Kondratyeva EI, Shabalova LA, Pivkina NV, Zhilina SV, Voronkova AYu et al. Microflora of the respiratory tract in patients with cystic fibrosis and sensitivity to antibiotics based on a 15-year follow-up (2000–2015 years). Meditsinskiy Sovet. 2016;(15):84–89. (In Russ.) https://doi.org/10.21518/2079-701X-2016-15-84-89.

22. Laine L, Perry JD, Lee J, Oliver M, James AL, De La Foata C et al. A novel chromogenic medium for isolation of Pseudomonas aeruginosa from the sputa of cystic fibrosis patients. J Cyst Fibros. 2009;8(2):143–149. https://doi.org/10.1016/j.jcf.2008.11.003.

23. Козлов РС, Сухорукова МВ, Эйдельштейн МВ, Иванчик НВ, Склеенова ЕЮ, Романов АВ и др. Определение чувствительности микроорганизмов к антимикробным препаратам: рекомендации МАКМАХ. Версия 2021-01. М.; 2021. 225 с. Режим доступа: https://www.antibiotic.ru/files/321/clrec-dsma2021.pdf.

24. Humphries RM, Green DA, Schuetz AN, Bergman Y, Lewis S, Yee R et al. Multicenter Evaluation of Colistin Broth Disk Elution and Colistin Agar Test: a Report from the Clinical and Laboratory Standards Institute. J Clin Microbiol. 2019;57(11):e01269-19. https://doi.org/10.1128/JCM.01269-19.